https://www.fortunebusinessinsights.com/glp-1-receptor-agonist-market-112827
GLP-1 Receptor Agonist Market Supported by
Long-Term Efficacy and Safety Evidence | 2032
Forecast
The GLP-1 receptor agonist market is focused on therapies widely used for managing type 2
diabetes and obesity. These drugs work by mimicking the natural GLP-1 hormone, which helps regulate
blood sugar, improve insulin secretion, slow digestion, and reduce appetite. Rising global rates of diabetes,
obesity, and related lifestyle disorders are key drivers for market growth. In addition to blood sugar
control, GLP-1 receptor agonists have shown benefits in weight management and cardiovascular
health, making them increasingly popular among patients and healthcare providers.
According to Fortune Business Insights, the global GLP-1 receptor agonist market was valued at USD 52.08
billion in 2024 and is projected to grow from USD 62.83 billion in 2025 to USD 186.64 billion by 2032,
exhibiting a compound annual growth rate (CAGR) of 16.8% during the forecast period. In 2024, North
America dominated the market with a 55.51% share.
Key Companies in the Market
Eli Lilly and Company (U.S.)
Sanofi (France)
Novo Nordisk A/S (Denmark)
AstraZeneca (U.K.)
Pfizer, Inc. (U.S.)
Glenmark Pharmaceuticals Limited (India)
Teva Pharmaceutical Industries Ltd. (Israel)
Key Industry Development
In June 2024, Novo Nordisk A/S entered a strategic collaboration with Biosplice Therapeutics, Inc., aiming to
develop a new drug candidate for diabetes treatment—highlighting the industry's commitment to pioneering
R&D.
Market Drivers & Restraints
Drivers
The accelerating prevalence of type 2 diabetes and obesity worldwide is a driving force behind market
expansion. Coupled with continuous advancements in drug formulations and the extension of therapeutic
applications beyond diabetes—such as for obesity and potential cardiovascular indications—the market is
poised for exponential growth. Innovations like oral formulations, combination therapies, strategic
partnerships, and a shift towards personalized medicine are further fueling momentum.
Restraints
A prominent challenge remains the shortage of GLP-1 agonists, brought on by soaring demand across
obesity and diabetes treatments. Nevertheless, manufacturers are actively addressing supply issues by
expanding their production capacities.
Market Report Coverage
The Fortune Business Insights report delivers a comprehensive breakdown—spanning market segments such
as drug type, route of administration, age group, indication, distribution channel, and regional analysis. It
includes a detailed forecast alongside assessments of current market dynamics, the impact of COVID-19,
and evolving trends. Competitive market shares, segmentation insights, and growth catalysts are all
included.
Market Competitive Landscape
The GLP-1 receptor agonist market is notably consolidated. Novo Nordisk A/S leads with a significant share,
powered by popular products like Ozempic and Rybelsus. Eli Lilly & Company holds a solid presence through
new product launches and strategic alliances. Sanofi and AstraZeneca are actively enhancing their positions
by securing regulatory approvals and entering partnerships to diversify their offerings.
https://www.fortunebusinessinsights.com/glp-1-receptor-agonist-market-112827
Market Segments
By Drug Type
Semaglutide holds the largest segment share, buoyed by superior glycemic control, weight-loss efficacy,
multi-indication approvals, and availability in both injectable and oral formats.
By Route of Administration
The parenteral (injectable) segment dominated in 2024, largely due to the widespread use of subcutaneous
GLP-1 agonists like dulaglutide (Trulicity). However, the oral segment, represented by medications like
Rybelsus (oral semaglutide), is expected to grow at a faster CAGR, driven by patient preference for non-
injectable options and formulation breakthroughs.
By Indication
The diabetes segment continues to lead globally, thanks to GLP-1 agonists’ ability to reduce blood glucose,
stimulate insulin, and inhibit glucagon. Meanwhile, the obesity indication is anticipated to witness the
highest growth rate as regulatory approvals expand for weight management and as companies pursue
clinical trials—particularly in combination therapies.
By Distribution Channel
Hospital pharmacies currently dominate the distribution landscape, benefiting from increasing
hospitalizations and collaborations with pharmaceutical firms. Retail pharmacies rank second in growth,
aided by partnerships and expansion—highlighted by Reliance Retail’s announcement in January 2023 to
launch over 2,000 standalone pharmacy stores. Online pharmacies are emerging, especially in digitally
advanced regions, due to the convenience of home delivery and improved access.
Explore the full research report with detailed insights and
TOC:https://www.fortunebusinessinsights.com/glp-1-receptor-agonist-market-112827
Market Regional Insights
North America
North America commanded 55.51 % of the global market in 2024, with a valuation of USD 28.91 billion. The
region’s dominance stems from elevated healthcare spending, high prevalence of obesity and diabetes, and
substantial R&D investments by major players like Eli Lilly & Company, which injected USD 1.8 billion into
manufacturing capacity in September 2024.
Europe
Europe stands as the second-largest market, driven by the presence of leading pharmaceutical companies
such as Novo Nordisk and intensified R&D activity and product launches.
Asia Pacific
The Asia Pacific region is poised to exhibit strong growth, powered by rising rates of obesity and diabetes,
growing awareness, and escalating healthcare investments. The World Obesity Atlas (2023) projects obesity
prevalence to more than double in regions like the Western Pacific and Southeast Asia between 2020 and
2035, amplifying demand in the region.
Latin America
Latin America is on track for considerable expansion, aligned with government initiatives, strategic
partnerships, urbanization, and health infrastructure improvements.
Future Market Scope
Looking ahead, the GLP-1 receptor agonist market is set for transformative expansion as companies
advance oral and combination therapies, integrate AI and digital health tools, and expand distribution
networks. With unmet needs in developing regions, manufacturing enhancements, and shifting patient
preferences, the broader adoption of GLP-1 therapies is on the horizon, charting a promising future for
global diabetes and obesity management.
Conclusion
The GLP-1 receptor agonist market stands at a significant inflection point. With a projected leap from USD
52.08 billion in 2024 to USD 186.64 billion by 2032, the market’s trajectory is fueled by innovation,
urgent public health needs, and strategic industry collaboration. Stakeholders—including pharmaceutical
developers, investors, policymakers, and healthcare providers—are presented with an opportunity to
capitalize on what promises to be a compelling growth story in modern therapeutics.
About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all
sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them
address unique challenges. Our goal is to empower clients with holistic market intelligence and offer
granular insights into the market they operate in.
At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and
recommendations that help them navigate technological and market changes. Our consulting services are
designed to help companies uncover hidden opportunities and address competitive challenges.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com